Opdivo-Yervoy Combo Shrinks Aggressive Neuroendocrine Tumors, Phase 2 Trial Shows
News
A combination treatment with Opdivo (nivolumab) and Yervoy (ipilimumab) reduces tumor size in four of 10 patients with aggressive neuroendocrine carcinoma, according to early results of a Phase 2 trial. ... Read more